Panacea Bio share price surges 6% after completing enrollment of study participants for Dengiall Phase-III trial
Panacea Bio’s share price surged as much as 6% to 407.60 apiece in Thursday’s trading session after the company said it has completed enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll. “In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we…
